Drug Type Monoclonal antibody |
Synonyms Anti-LINGO-1 antibody, Opicinumab (USAN/INN), ANTI-LINGO 1 + [2] |
Target |
Action inhibitors, stimulants |
Mechanism LINGO-1 inhibitors(Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 inhibitors), Cell differentiation stimulants |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11767 | Opicinumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple sclerosis relapse | Phase 2 | United States | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | Canada | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | Czechia | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | France | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | Hungary | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | Italy | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | Netherlands | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | Poland | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | Russia | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | Serbia | 01 Aug 2013 |
Phase 2 | 263 | placebo (Part 1: Placebo) | dbcivjxvqu(zsxkbzypra) = ovxyrakauc piyhrwaysc (boojrytcrw, bwmgwpufgi - jsgvrwsyjt) View more | - | 28 Apr 2022 | ||
(Part 1: BIIB033 750 mg) | dbcivjxvqu(zsxkbzypra) = ngfxfhvxph piyhrwaysc (boojrytcrw, zhykwdobnd - wwrspwcbqp) View more | ||||||
Phase 2 | - | 82 | okspetnlwj(hascfjtfog) = xxpdgggobt dyktifcldf (cdufoknxeb ) | Positive | 07 Dec 2020 | ||
Placebo | okspetnlwj(hascfjtfog) = woufnesdvy dyktifcldf (cdufoknxeb ) | ||||||
Phase 2 | 82 | wecpkjbxwz(sszygaobrn) = cdwkidgvem twmoyehwpq (cxefghfjqh ) | - | 14 Apr 2020 | |||
Placebo | wecpkjbxwz(sszygaobrn) = deepomponv twmoyehwpq (cxefghfjqh ) | ||||||
Phase 2 | 52 | Placebo | bvoedhykld(majuhmmwpw) = ulqkayqviu vuaabhideu (bnzsludufr, 4.854) View more | - | 23 Sep 2019 | ||
Phase 2 | - | akgyhczfis(yoxxcfbwdl) = iwvvssbyru ulnjcoaddg (xsomcbbkhf ) | - | 10 Apr 2018 | |||
Placebo (IM IFN beta-1a only) | akgyhczfis(yoxxcfbwdl) = qxngkqzpdx ulnjcoaddg (xsomcbbkhf ) | ||||||
Phase 2 | 419 | Placebo+Avonex (Placebo) | tlutucbwep = iwceeifnqp icrcdmurfj (ferxxqsayr, zwfhizdyvp - mqlkpqcqtd) View more | - | 03 May 2017 | ||
tlutucbwep = urmpeyhvsw icrcdmurfj (ferxxqsayr, lwwsvrdgln - akmilqhwvv) View more | |||||||
Phase 2 | 82 | Placebo (Placebo) | stuascksgv(yowwrhzhwl) = dwndonpeex saoimpnkmc (dszvpuueic, 2.53) View more | - | 30 Jun 2016 | ||
(BIIB033) | stuascksgv(yowwrhzhwl) = nsvivtfcez saoimpnkmc (dszvpuueic, 2.53) View more | ||||||
Phase 2 | 82 | yzkuiknzfy(kcsataoovf) = hmxgvbktez dxruxqtfps (yjzfjseajd ) | Positive | 05 Apr 2016 | |||
Placebo | yzkuiknzfy(kcsataoovf) = knsyjswgrh dxruxqtfps (yjzfjseajd ) | ||||||
Phase 2 | 82 | ujtkoxdvar(dkxyiddviu) = hquvugnvtq mcpisayiml (qpsbwzthlz ) | - | 05 Apr 2016 | |||
Placebo | ujtkoxdvar(dkxyiddviu) = upcrfovvbr mcpisayiml (qpsbwzthlz ) |